Background: CDKN1C (also known as p57 KIP2 ) is a cyclin-dependent kinase inhibitor previously implicated in several types of human cancer. Its family members (CDKN1A/p21 CIP1 and B/p27 KIP1 ) have been implicated in breast cancer, but information about CDKN1C's role is limited. We hypothesized that decreased CDKN1C may be involved in human breast carcinogenesis in vivo.
Background
Cyclin-dependent kinases (CDK) are a family of enzymes that govern the mammalian cell cycle (among other functions) and whose aberrant upregulation can lead to oncogenic effects. Consequently, proteins that negatively regulate CDKs, cyclin-dependent kinase inhibitors (CDKNs), are strong candidate tumor suppressor genes. CDKNs fall into two families. The CDKN1 family contains three members, called CDKN1A (also known as p21 CIP ) [1] , CDKN1B (also known as p27 KIP1 ) [2, 3] and CDKN1C (also known as p57 KIP2 ) [4, 5] . CDKN1A and B play important and complex roles in breast cancer, but knowledge of CDKN1C's role is limited. The goal of this study is to examine whether CDKN1C is implicated in human breast cancers in vivo.
CDKN1C is a tight-binding inhibitor of several G1 cyclin/ CDK complexes and a negative regulator of the cell cycle at the G1 checkpoint (for overview see [6] ). The protein is widely expressed and located in the nucleus. The gene lies within an imprinted region, at chromosome 11p15.5-p15.4, and undergoes incomplete paternal imprinting, i.e., the maternal allele is expressed preferentially [7] . CDKN1C dysregulation -usually assessed as gene methylation or decreased mRNA expression -is seen in multiple types of sporadic cancers (adrenal [8, 9] , head and neck [10, 11] , gastrointestinal [12] [13] [14] [15] , urothelial [16, 17] and lung carcinomas [18] [19] [20] ), as well as in gestational trophoblastic disease [21] , Wilms' tumor [22] and the Beckwith-Wiedemann syndrome associated with organ overgrowth [23] . Over-expression, or re-expression, of the gene in vitro slows proliferation and shifts many cell types into G1 [24] [25] [26] .
Several in vitro observations support the hypothesis that CDKN1C is implicated in breast tumorigenesis. First, decreased CDKN1C expression occurs during human mammary epithelial cell immortalization [27] . Second, CDKN1C may be regulated by estradiol in mammary carcinoma cells [28] . Finally, CDKN1C may be regulated by epigallocatechin-3-gallate (EGCG), a polyphenol in green tea with anti-oxidant effects that may have cancer-suppressive effects in general, and in breast cancer in particular [29-32].
CDKN1C's role in breast cancer in vivo has been considered previously, but data are limited. 11p15 undergoes allele imbalance (AI) or loss of heterozygosity (LOH) in 35-40% of breast cancers [33-35], but CDKN1C does not appear to be commonly mutated or rearranged [34, 36] . The gene is hypermethylated in ~45% of primary tumors [18] . Gene expression data available in repositories [37] reveals that CDKN1C mRNA is present at relatively low levels in both normal and cancerous breast tissue. We are not aware of any reports examining CDKN1C protein expression in human breast cancers.
Taken together, these data led us to investigate CDKN1C's potential role as a tumor suppressor in breast cancer in vivo. We speculated that the gene itself would not undergo genomic alterations detectable by AI/LOH, but that CDKN1C mRNA and protein levels would be diminished. To ascertain whether the genetic alterations were present in the epithelial compartment, as presumed, all tissues examined were microdissected.
Methods

Tissue samples
After obtaining Boston University Medical Center institutional review board approval, randomly-selected, de-identified, existing tissue samples not needed for diagnosis were collected from 91 independent breast cancer cases from Boston University Medical Center. In 87 cases, tissues had been formalin-fixed and paraffin embedded (FFPE). In 10 cases, tissues had been snap frozen, embedded in optimal cutting temperature (OCT) medium and stored at -80°C. One or more experienced breast pathologist (AdlM, RP) reviewed all sections for accurate histologic diagnoses.
Microdissection, DNA isolation and AI/LOH analysis
These procedures were carried out as described previously [38] [39] [40] . FFPE or OCT embedded blocks were sectioned and microdissected (PixCell, Arcturus Engineering, Mountain View, CA) to isolate DNA from normal epithelium, tumor and control tissue. PCRs were performed using nine microsatellite probes: four at 11p15.4-.5 (D11s2071, D11s1318, THO1 and KIP2 -which is located in a CDKN1C intron); 3 at 11q (PYGM (at 11q13.1) and D11s1818 and D11s1819 (at 11q23.1-.2), and one each at 3p24.2-5 (D3s1283) and 7q31 (D7s486), which served as control loci. Either a radioactive or fluorescent [41] label was incorporated into the reactions. The normal pattern at each microsatellite probe was defined as its pattern in normal tissue of each individual (skin, lymph node or normal breast epithelium). AI/LOH was defined as an imbalance of 33% or more (allele ratio >1.50 or <0.67). All abnormalities were demonstrated at least twice with equivalent results.
Microdissection, RNA isolation and qPCR
Cases with available tissue were selected at random and their OCT-embedded blocks were sectioned and microdissected with the aid of pathologists to isolate normal breast epithelium (terminal ducto-lobular units, or TDLUs) and tumor [42] . Control RNA was extracted (Qiagen RNeasy Midi Kit, Qiagen, Valencia CA) from bulk normal-appearing tissue from a cancer-containing breast stored in RNAlater (Qiagen). To prevent clogging of the RNeasy column by excess fat, the tissue homogenate was spun at 6100 rpm for 10 minutes at 4°C and only the aqueous layer was used for RNA purification. All RNA samples were quantified spectrophotometrically (Nanodrop Technologies, Wilmington, DE), and 1.0 ng RNA from each sample was run on an RNA 6000 Pico LabChip for the Agilent Bioanalyzer 2100 (Agilent Technologies, Waldbronn, Germany) to confirm quality.
To produce cDNA, RT-PCR was performed on 5.0 ng of each microdissected RNA sample using Taqman Gold RT-PCR reagents (Applied Biosystems, Foster City, CA) in a 25 μl reaction. Quantitative real-time PCR (qPCR) was performed using Taqman Universal PCR Mastermix (ABI), in independent 25 μl reactions consisting of 11.25 μl cDNA solution and an Assay on Demand (ABI) for CDKN1C or glucuronidase B (GUSB), an endogenous control gene located at 7q31 whose expression is similar in normal and malignant breast tissue [43] . The CDKN1C primers are designed to amplify the 3' end of the first and the 5' end of the second exon. QPCR was performed using an ABI Prism 7000 Sequence Detection System and analyzed using the SDS version 1.1 software (ABI). Standard curves using the control RNA isolated from bulk normal breast tissue were performed with every reaction. All reactions were done twice, and an independent RT-PCR and qPCR was performed for each replicate to reduce error and allow greater accuracy when comparing reactions done at different times.
Immunohistochemistry (IHC)
Cases with available FFPE blocks were selected at random and 5 μm sections were cut from FFPE blocks, mounted on positively charged glass slides, dried at 60°C for 1 hr, and deparaffinized. Endogenous peroxidase activity was quenched with hydrogen peroxide/methanol for 15 mins. Antigen retrieval was achieved by microwaving the slides in a citrate buffer (Citrate Plus, Biogenex, San Ramon, CA) on the high setting for 3-5 mins followed by the medium setting for 8 mins. After washing, sections were incubated for 1 hr at room temperature with a rabbit polyclonal anti-CDKN1C antibody directed against the carboxy-terminus of the protein (C-20, Santa Cruz, CA) at a 1:2000 dilution of the stock solution. The negative control was a rabbit polyclonal antibody pool (Biogenex). To localize sites of primary antibody binding, sections were incubated with a biotin-labeled goat anti-rabbit secondary antibody (20 mins) followed by streptavidin-HRP (20 mins) (LP000-UL, Biogenex). After washing, sections were exposed to the chromagen diaminobenzidine for 10 sec. before counterstaining with hematoxylin for 30 sec.
Two pathologists [RP, AdlM] independently reviewed the slides and recorded the proportion of cells with nuclear staining in each type of lesion (normal epithelium, CIS, IC). The proportion of cells with staining was assessed separately for the myoepithelial and luminal regions. The intensity of staining was graded using a semi-quantitative 0-3 + scale (0 = no staining, 1 + = weak, 2 + = moderate, 3 + = strong). Placenta served as the positive control.
Statistical analyses
To compare rates of AI/LOH at separate probes, Fisher's exact test was used. For the RNA expression data, Friedman's two-way non-parametric analysis of variance (ANOVA) was used to compare two matched groups (normal and tumor) and each group was measured two times. Within each sample, the values of the difference between the Ct values (ΔCt) of CDKN1C and GUSB were ranked. Then the ranks were compared between the normal and tumor groups to form a chi-square statistic with one degree of freedom. For the IHC data, Fisher's exact test was used to test the difference between two proportions (normal and CIS, normal and IC, or CIS and IC).
Results
Cases
Ninety-one breast cancers were analyzed. Of these, DNA from 82 were analyzed for AI/LOH at four 11p15.5 and five control loci, RNA from ten cases were analyzed for expression of CDKN1C mRNA via qPCR, and tissues from 20 cases were analyzed for staining of CDKN1C protein via IHC. The clinical-pathologic characteristics of the cases used suggest that they represent an unselected group of breast cancers. These characteristics are summarized in Table 1 .
DNA 82 breast cancer cases were analyzed for AI/LOH (nine CIS, 73 IC). The results are summarized in Table 2 . AI/ LOH at one or more markers on 11p15 was seen in 28/73 (38%) informative tumors, consistent with previous reports [33, 34, [44] [45] [46] . In contrast, AI/LOH at CDKN1C itself was seen in 3/16 (19%) informative tumors, a level consistent with a background or non-specific rate. Results were the same from frozen and FFPE samples. There were no statistical differences between the rates of AI/LOH at CDKN1C and any other 11p15 probe.
RNA
Cancer and paired normal epithelium from ten invasive breast cancers were analyzed for CDKN1C RNA expression by qPCR. We found reduced expression of CDKN1C in 9/10 (90%) cancers relative to its paired normal epithelium, and normalized against GUSB (see Figure 1 ). The ΔCt between CDKN1C and GUSB for each normal sample was compared to its paired tumor sample to generate the relative expression of CDKN1C mRNA between tumor and normal. This difference in relative expression of mRNA between the cancer and normal groups was signif-icant (p < 0.0001). The fold changes in mRNA level were moderate. As shown in Figure 1 , CDKN1C mRNA levels in nine cancers ranged from 2 -60% of normal and in one cancer was 282% of normal.
Protein
Twenty breast cancer cases were examined for CDKN1C protein levels using IHC. Figure 2 shows representative examples of staining. Overall, there was less CDKN1C staining in both CIS and IC, compared to normal epithelium. As shown in Figure 3a , staining of any intensity at any location was present in 19/20 (95%) normal epithelial samples, compared to 7/14 (50%) CIS (p = 0.004) and 5/18 (28%) IC (p = 0.00002). The difference between CIS and IC was not significant.
CDKN1C protein expression did not appear to be distributed uniformly between the luminal and myoepithelial layers. In normal lobules, the positively staining cells were predominantly in the myoepithelial layer, as seen in Figure 2b . These cells stained intensely, usually 2+ -3+. On average, 46% of myoepithelial layer cells, from 17/20 (85%) cases, stained for CDKN1C. In contrast, no myoepithelial layer cells (0%) stained for CDKN1C in any CIS (0/14 (0%) cases). An example is shown in Figure 2c . By definition, IC does not have a myoepithelial layer. In luminal cells, CDKN1C staining was generally more focal, less common, and less intense (1+ -2+) than in myoepithelial layer cells. In addition, luminal cell CDKN1C staining was fairly similar across the three histologies. In normal lobules, luminal cell staining was confined to 2% of cells, from 4/20 (20%) cases, in CIS it was limited to 6% of cells, from 7/14 (50%) cases, and IC it was seen in 2% of cells from 5/18 (28%) cases. These results are depicted in Figure 3b . Table 3 presents the IHC results for each case.
Integration of DNA, RNA, and protein data
There were six cases with DNA, mRNA and protein data. The findings in these cases were consistent with those of the full group. None of the six had AI/LOH at CDKN1C, but all had decreased mRNA levels. CDKN1C protein staining was present in normal epithelium of 6/6 (100%) cases (4 in the myoepithelial and 2 in luminal area cells), and complete loss of staining was seen in 3/4 (75%) CIS and 5/5 (100%) IC. These data are summarized in Table 4 .
Clinical-pathological correlation
We tested for associations between AI/LOH at each DNA marker,CDKN1C mRNA expression and protein staining, and subject age, tumor histology, grade, ER/PR or HER2 status. The only association seen was between AI/LOH at the THO1 marker and lack of ER/PR expression (p = 0.036). The other chromosome 11p markers, including CDKN1C, were not significantly associated, nor was AI/ LOH at THO1 associated with other clinical-pathological features. 
Discussion
We speculated that CDKN1C might, like its family members, be implicated in breast carcinogenesis in vivo. Therefore, we investigated its DNA, mRNA and protein levels in a series of primary breast cancers, compared to paired normal breast epithelium. Using microdissected samples, we found that the gene does not appear to undergo AI/LOH, but its mRNA level is reduced in 90% of cancers, and its protein is completely absent in 50% of in situ and 72% of invasive cancers. The reduction appears primarily due to loss of CDKN1C expression from myoepithelial layer cells, which stained intensely in 17/20 (85%) normal lobules, but in 0/14 (0%) CIS (p < 0.00001). AI/LOH of the 11p15.4-5 region in general and decreased expression of CDKN1C was not clearly associated with tumor grade, histology, ER, PR or HER2 status. These data suggest CDKN1C acts as a tumor suppressor in breast cancer, perhaps in myoepithelial cells, and that its function may be lost at or before the appearance of CIS. This study does not investigate the mechanism of the gene's inactivation, but our results are consistent with an epigenetic process, or RNA interference, although other processes could be involved as well.
These data raise several points for consideration. Gene expression profiling data available at Gene Expression Omnibus (last accessed 01-10-08 [37] ) indicate that CDKN1C mRNA expression is relatively low and not consistently different between normal and cancerous breast tissue. The data from primary tissues generally derive from analysis of bulk normal and tumor samples that contain a heterogeneous mix of cells. In contrast, we saw small but widespread decreases in CDKN1C mRNA expression in malignant epithelium, compared to normal. We may have observed subtle but consistent decreases because we microdissected our samples, which enriched them for epithelium and unmasked the gene's potentially important role. This speculation is supported by our finding that in normal epithelium the expression appears localized mainly in myoepithelium, which constitutes only a fraction of the cells of the normal lobule. It is believed that a functioning myoepithelium may suppress progression of the neoplastic luminal cells [47] . Loss of myoepithelial CDKN1C mRNA levels are decreased in primary breast cancers CDKN1C protein expression could participate in the dysregulation of this process, resulting in cancer progression. We note, however, that CDKN1C mRNA was not found to be differentially expressed in one study comparing myoepithelial with luminal cells [48] . This may reflect the techniques used, or effects of post-transcriptional modifications leading to lack of concordance between mRNA and protein. Furthermore, we cannot distinguish whether the decreased CDKN1C mRNA expression we observe in microdissected epithelium is due to all cells having moderately decreased expression, or to a subpopulation [e.g., myoepithelial cells] having dramatically decreased expression, or to a decrease in the number of cells [e.g., myoepithelial cells] with constant high expression. Future experiments to address this question will be important.
Secondly, we see decreased mRNA in nearly all cases, but the gene is reported to be methylated in only half that number [18] . One potential explanation for this discrepancy is that gene methylation may really be present in nearly all cases, but has been hidden due to "contamination" by heterogeneous non-malignant cells with an unmethylated gene. Another possibility is that alternative mechanisms, such as histone modification, or post-transcriptional effects, may lead to decreased RNA and, subsequently, protein, levels. Decreased CDKN1C mRNA expression due to several mechanisms has recently been described in primary pancreatic neoplasms [15] . redundancy, but there could be subsets of cells within breast tissue with restricted expression of one or another CDKN1 family member [49] . The CDKN1 family may parallel the CDKN2 family, which also contains several members with clear roles in carcinogenesis and one member, (CDKN2B, or p15), whose role is unresolved.
There are several potential limitations to the present study. First, our evaluation of DNA alterations is not comprehensive. We opted for this approach because previous studies found sequence alterations to be uncommon, and gene methylation to be present in nearly half of breast cancers. Second, the number of cases examined is relatively small. However, the results are remarkably uniform.
Third, we used a single set of primers and a single antibody to examine RNA and protein levels, respectively, and thus may not have detected uncharacterized splice variants or aberrant proteins. CDKN1C contains 3 exons; the second and third are coding and produce two isoforms by alternative splicing. The long 316 amino acid (aa) isoform is unprocessed, and the short, 305 aa isoform is missing the first, or amino-terminal, 11 aa. Since we used an antibody directed at a carboxy-terminal epitope, both isoforms should have been detected. The RNA primers spanned the first and second exon and should have detected all transcripts. Fourth, we defined myoepithelial cells by histologic appearance and location, not by additional stains. Finally, this study found a strong association between CDKN1C and breast cancer, but cannot determine causality.
Conclusion
We find that the CDKN1C gene does not appear to undergo frequent genetic alteration, as measured by AI/ LOH, but that mRNA and protein levels are decreased in the large majority of breast cancers compared to paired normal epithelium. The reduction in protein expression appears mainly due to loss of expression in normal lobule's myoepithelial layer cells. Combining these data with existing knowledge of the gene's regulation and the protein's function, suggest that CDKN1C is a tumor suppressor that could act early in breast carcinogenesis, perhaps in the myoepithelial compartment.
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